B P11 C95 Hemostasis, Thrombosis, Fibrinolysis and Cardiovascular Disease Flashcards
Usual dose of Aspirin
75 - 325 mg daily
There is no evidence that higher-dose aspirin is more effective than lower doses, and some meta-analyses suggest reduced efficacy with higher doses
To reduce the risk for bleeding, thienopyridine therapy must be stopped approximately ________ before surgery.
5 days
Usual dose of Clopidogrel
75 mg once a day
Because its onset of action is delayed for several days, 300- to 600-mg loading doses of clopidogrel are given when rapid ADP receptor blockade is desired
Usual dose of Prasugrel
10 mg once a day
After a loading dose of 60 mg, prasugrel is given once daily at a dose of 10 mg. 38 Patients older than 75 years or weighing less than 60 kg should receive a daily prasugrel dose of 5 mg
Contraindicated those with a history of cerebrovascular disease.
Usual dose of Ticagrelor
90 mg twice a day
Ticagrelor is initiated with an oral loading dose of 180 mg followed by 90 mg twice daily.
Usual dose of Heparin for
1. Prophylaxis
2. ACS
3. VTE
- Prophylaxis - 5000 units subcutaneously two or three times
- ACS - 5000 units or 70 units/kg, a heparin infusion rate of 12 to 15 units/kg/hr
- VTE - 5000 units or 80 units/kg, followed by an infusion of 18 units/kg/hr (fibrin content of extensive deep vein thrombi is greater than that of coronary thrombi)
Usual dose of Heparin for
1. Prophylaxis
2. ACS
3. VTE
- Prophylaxis - 5000 units subcutaneously two or three times
- ACS - 5000 units or 70 units/kg, a heparin infusion rate of 12 to 15 units/kg/hr
- VTE - 5000 units or 80 units/kg, followed by an infusion of 18 units/kg/hr (fibrin content of extensive deep vein thrombi is greater than that of coronary thrombi)
_____________ Antibody-mediated process triggered by antibodies against n antigens on PF4
Typically occurs _______ days after initiation
More common among ________, ____________
Heparin-induced thrombocytopenia (HIT)
5 - 14 days
Surgical, females
Venous > arterial thrombosis
UFH than LMWH
Dosing of LMWH for
1. Prophylaxis
2. VTE
3. ACS
- Prophylaxis - once daily subcutaneous doses of 4000 to 5000 units; 2500 to 3000 units 2x a day
- VTE - 150 to 200 units/kg OD; 100 units/kg BID
- ACS - 100 to 120 units/kg BID
Dosing of Fondaparinux for
1. Prophylaxis
2. VTE
3. ACS
- Prophylaxis - 2.5 mg once daily
- VTE - 7.5 mg once daily. The dosage can be reduced to 5 mg once daily for those weighing less than 50 kg and increased to 10 mg for those heavier than 100 kg
- ACS - 2.5 mg once daily
Dosing of Dabigatran for
1. Stroke prevention
2. VTE
3. Thromboprophylaxis
- Stroke prevention - 150 mg twice daily, with a reduction to 75 mg twice daily in those with a creatinine clearance of 15 to 30 mL/min
- VTE - 150 mg twice daily provided the creatinine clearance is over 30 mL/min after a 5 days course of parenteral anticoagulant
- Thromboprophylaxis - 220 mg once daily
Dosing of Rivaroxaban for
1. Stroke prevention
2. VTE
3. Prophylaxis
- Stroke prevention - 20 mg once daily, with a reduction to 15 mg once daily in patients with a creatinine clearance of 15 to 49 mL/min
- VTE - 15 mg twice daily for 21 days and is then reduced to 20 mg once daily
- Prophylaxis - 10 mg once daily
For secondary prevention of adverse cardiac or limb events in patients with coronary or peripheral artery disease, rivaroxaban is given at a dose of 2.5 mg twice daily on top of aspirin (81 or 100 mg once daily).
Dosing of Apixaban for
1. Stroke prevention
2. VTE
3. Thromboprophylaxis
- Stroke prevention - 5 mg twice daily, with a reduction to 2.5 mg twice daily for patients with at least two of the “ABC” criteria (i.e., age over 80 years, body weight under 60 kg, and creatinine over 1.5 g/dL)
- VTE - 10 mg twice daily for 7 days and is then reduced to 5 mg twice daily
- Thromboprophylaxis - 2.5 mg twice daily
Dosing of Edoxaban for
1. Stroke prevention
2. VTE
3. Thromboprophylaxis
- Stroke prevention - 60 mg once daily for patients with a creatinine clearance of 50 to 95 mL/min and with a reduction to 30 mg once daily for patients with any one of the following criteria: creatinine clearance 15 to 50 mL/min body weight of 60 kg or less, or use of potent P-glycoprotein inhibitors, such as verapamil or quinidine.
- VTE - same as above after a 5 day course of parenteral anticoagulation
- Thromboprophylaxis - edoxaban is not licensed for this indication except in Japan
Give the reversal agent for
Dabigatran
Rivaroxaban
Apixaban
Edoxaban
Dabigatran - Idarucizumab
Rivaroxaban, apixaban, edoxaban and heparins - Andexanet Alfa